COCP - Company ID 0001412486
The table below shows Cocrystal Pharma, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $2.01M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $5.05M | $12.54M | $15.17M | $12.39M | $8.79M | $6.03M |
| SG&A | $3.96M |
Cocrystal Pharma, Inc. reported annual revenue of $2.01M for fiscal year 2020. That is down 69.3% from $6.56M in fiscal 2019. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.34M |
| $5.99M |
| $5.75M |
| $5.43M |
| $5.57M |
| Operating income | -$9.02M | -$17.88M | -$18.56M | -$38.83M | -$14.22M | -$9.59M |
| Income tax | - | - | - | - | - | - |
| Net income | -$8.83M | -$17.50M | -$17.98M | -$38.84M | -$14.19M | -$9.65M |
| EPS (diluted) | -$0.78 | -$1.72 | -$1.87 | -$4.77 | - | - |